Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.
| 3.45 | |
| 3.27 | |
| - | |
| 3.4566 | |
| 3.25 | |
| 2.26-13.61 | |
| 19 237 K | |
| 5 576 K | |
| 278 K | |
| -0.12 | |
| -0.257 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Étude de validation : La plateforme IA-Immunology™ développée par Evaxion démontre une conception réussie de vaccins ciblés contre les formes de cancer du sang par le ciblage d’une nouvelle...
Proof of Concept – Die AI-Immunology™-Plattform von Evaxion ist erfolgreich bei der Entwicklung von Präzisions-Krebsimpfstoffen für hämatologische Krebserkrankungen, die auf eine neue Klasse vo...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
